Agents that deplete Tregs in cancer patients could therefore improve the efficacy of therapeutic cancer vaccines. We compared the efficiency of three potentially Tregdepleting agents administered to vaccinated melanoma patients by measuring blood Treg frequencies with an epigenetic assay that is not confounded by the presence of activated non regulatory T cells. Our results show that neither daclizumab, nor lowdose cyclophosphamide or denileukin diftitox induced a more than 50% decrease in 
Introduction
Antigens on human tumor cells that are recognized by T lymphocytes can be used to develop tumor-specific active immunotherapy. Several small clinical trials have investigated the therapeutic and immunological efficacy of vaccinating advanced-stage cancer patients with defined tumor antigens. In previously published studies of patients with metastatic melanoma, about 5% of vaccinated patients showed a complete or partial clinical response, whereas an additional 10% displayed some evidence of tumor regression without clear clinical benefit (1, 2) .
Because most antitumor vaccination modalities are not associated with serious adverse effects, therapeutic vaccination with defined antigens remains a promising approach, provided that its clinical efficacy increases substantially. + T cells that specialize in the inhibition of immune responses (6) . Their development and function depends on the transcription factor FOXP3, as illustrated by the severe Treg deficiency and autoimmune disease observed in patients with FOXP3 mutations (7) . In mice, there is ample evidence that Tregs inhibit spontaneous or vaccine-induced anti-tumor immune responses (8) .
In cancer patients, however, this has remained difficult to prove, because of the lack of a good Treg marker. CD25, the alpha chain of the IL-2 receptor, is upregulated in all activated T cells. Moreover, while in mice, FOXP3 is restricted to the Treg lineage, in humans it is also detected in activated CD4 + T cells that are not suppressive (9) (10) (11) . Recently, it was shown that in humans, the demethylation of a conserved region in the FOXP3 intron 1 is strictly specific to Tregs (12) . This
Research. In the present study, we used MS-qPCR for FOXP3i1 to measure Treg frequency in melanoma patients enrolled in four independent clinical trials. Three of the trials combined cancer vaccines with either denileukin diftitox, cyclophosphamide, or the anti-CD25 humanized monoclonal antibody daclizumab.
To the best of our knowledge, this is the first comparison of these compounds using a truly Treg-specific parameter. The fourth trial combined vaccination with IL-2, which increases Tregs.
Research. 
Materials and Methods

Patients
Vaccination with peptide pulsed DCs combined to daclizumab
Inclusion criteria comprised AJCC stage IV melanoma with measureable disease parameters; additional inclusion criteria are described in (26) . DCs were generated from leukapheresis samples as previously described (27 were performed after the third and fourth vaccines. The study included an observation arm in which 21 patients received no other treatment beside surgery.
Analyses of clinical and immune responses will be described elsewhere 1 . PBMC samples from 16 patients were available for this retrospective study. 1 Filipazzi et al, manuscript in preparation.
Vaccination with peptide pulsed DC combined to denileukin diftitox
Stage III and IV metastatic melanoma patients were vaccinated with autologous DC pulsed with class I and class II peptides. Separate batches of DCs, prepared as previously described (28) of clinical and immune responses will be described elsewhere 2 . PBMC samples from 6 patients were available for this retrospective study.
Vaccination with peptide pulsed DCs combined to IL-2
Patients with AJCC stage III melanoma were enrolled in this study on the basis of the same additional inclusion criteria described for the DC + daclizumab study. Vaccines consisted of autologous mature DCs pulsed with gp100 and tyrosinase peptides and KLH injected into an inguinal clinically tumor-free lymph node under ultrasound guidance. A total of 22 patients received one cycle of four vaccinations every 2 weeks. In addition to the vaccines, 10 of the patients received daily low-dose IL-2 (9 MIU, s.c.) during one week. Analyses of clinical and immune responses will be described elsewhere 3 .
For all studies, approval from the local regulatory committee was obtained and patients gave written informed consent prior to inclusion.
2 Schuler-Thurner et al, manuscript in preparation. 3 Lesterhuis et al, manuscript in preparation.
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MS-qPCR for FOXP3i1
Genomic DNA (gDNA) was prepared from frozen pellets containing 4x10 5 Gene FOXP3 is located on the X chromosome. In female patients, one of the two copies of the X chromosome is inactivated by methylation.
Magnetic sorting of PBMC subsets
Total PBMCs from a hemochromatosis donor were purified on a Research. 
Frequency of Tregs in metastatic melanoma patients not receiving Tregdepleting agents
In this retrospective study, we measured the blood Tregs of patients with melanoma who were participating in three independent clinical trials that combined tumor vaccines with potential Treg-depleting agents, and in a fourth trial combining vaccines with IL-2. The numbers of included patients were small, and multiple samples were available for only nine patients who received neither a Treg-depleting agent nor IL-2. In these control patients, Treg frequency varied over time, with a maximum increase of 260% and decrease of 46% (Supplemental table S2 ). We therefore chose a conservative reduction of 50% to qualify patients as responders to the Treg-depleting agents.
Research. Figure 2A and Supplemental table S2 ). Compared to predaclizumab levels, a more than 50% decrease in Treg frequencies was observed in two out of seven and in two out of six patients who received the drug 8 and 4 days, respectively, before the first vaccine. These 55%-96% decreases were transient:
Treg frequencies returned to baseline levels after one month.
In the second trial 4 Figure 2C , none of the six evaluated patients had a more than 50% decrease in Treg frequency. PBMCs from patients in a fourth clinical trial, who received a vaccine with or without IL-2 6 . Stage III melanoma patients were injected four times at biweekly intervals with DCs pulsed with gp100 and tyrosinase peptides and KLH, as in the daclizumab trial. Two days after each injection, some patients received low-dose IL-2 (9 MIU, s.c. daily for one week). Using MS-qPCR for FOXP3i1, the mean Treg frequencies were shown to increase 3-fold after IL-2 was administered ( Figure   3A , left panel). Individual analyses showed this increase in all but one out of the six patients receiving IL-2, and in none out of the four patients who received the vaccine alone ( Figure 3B ). Treg increases were detectable 3 weeks after the first IL-2 injection, and persisted for at least 3 weeks after the last injection. Using flow cytometry, we also found increases in the frequencies of CD4 + cells expressing FOXP3 ( Figure 3A , middle panel, and Figure 3B ). The increases observed with MS-qPCR were slightly higher than those observed with flow cytometry, notably for patient 4.7 ( Figure 3B ). We have no definitive explanation for these differences.
Frequency of Tregs in patients receiving
The mean frequencies of total CD4 + cell did not vary between the different time points or groups of patients ( Figure 3A, right panel) . The results clearly confirmed 5 Schuler-Thurner et al., manuscript in preparation 6 Lesterhuis et al., manuscript in preparation
